The CRISPR IP battle is being fought between universities, not corporations. CRISPR aside, the IP situation in biotech and specifically in synthetic biology (parts-based biology) is not a good one. Currently there…
My take is that we will see it used on cell therapies like CAR-T. Id point out that Novartis and Intellia have signed a deal to this effect - see link below. Immunotherapy is likely a clear win for this kind of genome…
Hi there, this is Edward (I spoke at the HN London event a few weeks ago on CRISPR - https://vimeo.com/137001197). I'd encourage you to get in touch with us at Desktop Genetics. We are always on the lookout for talented…
The CRISPR IP battle is being fought between universities, not corporations. CRISPR aside, the IP situation in biotech and specifically in synthetic biology (parts-based biology) is not a good one. Currently there…
My take is that we will see it used on cell therapies like CAR-T. Id point out that Novartis and Intellia have signed a deal to this effect - see link below. Immunotherapy is likely a clear win for this kind of genome…
Hi there, this is Edward (I spoke at the HN London event a few weeks ago on CRISPR - https://vimeo.com/137001197). I'd encourage you to get in touch with us at Desktop Genetics. We are always on the lookout for talented…